SCHEMBL1965997

SCHEMBL1965997

CCOC(=O)c1c(O)c2cccn2n(Cc2ccccc2Cl)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.50
ALDH1A1 P00352 12/20 0.48
MAPT P10636 4/20 0.48
LMNA P02545 3/20 0.48
GAA P10253 3/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
L3MBTL1 Q9Y468 4/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
RECQL P46063 1/20 0.46
HTT P42858 1/20 0.45
HPGD P15428 4/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
PTGER3 P43115 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968107 0.87 KDM4E (0.50) KDM4EALDH1A1MAPTLMNAGAA
SCHEMBL1967350 0.87 KDM4E (0.54) KDM4EALDH1A1MAPTLMNAGAA
SCHEMBL1967127 0.85 KDM4E (0.48) KDM4EALDH1A1MAPTLMNAMAPK1
SCHEMBL1965742 0.85 KDM4E (0.47) KDM4EALDH1A1MAPTLMNAGAA
SCHEMBL1965910 0.82 ALDH1A1 (0.47) KDM4EALDH1A1MAPTLMNAGAA
SCHEMBL1966103 0.81 KMT2A (0.50) KDM4EALDH1A1MAPTLMNAMAPK1
SCHEMBL1966096 0.81 FEN1 (0.53) KDM4EALDH1A1MAPTLMNAGAA
SCHEMBL1968973 0.81 ALDH1A1 (0.43) KDM4EALDH1A1MAPTLMNAGAA
SCHEMBL1966882 0.80 ALDH1A1 (0.46) KDM4EALDH1A1MAPTLMNAGAA
SCHEMBL1966099 0.79 KDM4E (0.44) KDM4EALDH1A1MAPTLMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 KDM4E 471/4885ALDH1A1 268/4885MAPT 4198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.